BioLife Solns (NASDAQ: BLFS)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of BioLife Solns (NASDAQ: BLFS) through any online brokerage.
Other companies in BioLife Solns’s space includes: RxSight (NASDAQ:RXST), Meridian Bioscience (NASDAQ:VIVO), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for BioLife Solns (NASDAQ: BLFS) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting BLFS to fall to within 12 months (a possible -83.73% downside). 50 analyst firms have reported ratings in the last year.
The stock price for BioLife Solns (NASDAQ: BLFS) is $24.59 last updated August 12, 2022, 8:00 PM UTC.
The next BioLife Solns (BLFS) dividend date is projected to be Thursday, September 1, 2022.
BioLife Solns’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for BioLife Solns.
BioLife Solns is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.